LAB Straddle Strategy
LAB (Standard BioTools Inc.), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc.
LAB (Standard BioTools Inc.) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $394.3M, a trailing P/E of 5.01, a beta of 1.31 versus the broader market, a 52-week range of 0.87-1.72, average daily share volume of 2.6M, a public-listing history dating back to 2011, approximately 814 full-time employees. These structural characteristics shape how LAB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.31 indicates LAB has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. The trailing P/E of 5.01 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.
What is a straddle on LAB?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current LAB snapshot
As of May 13, 2026, spot at $1.00, ATM IV 117.10%, IV rank 21.43%, expected move 22.00%. The straddle on LAB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 36-day expiry.
Why this straddle structure on LAB specifically: LAB IV at 117.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a LAB straddle, with a market-implied 1-standard-deviation move of approximately 22.00% (roughly $0.22 on the underlying). The 36-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LAB expiries trade a higher absolute premium for lower per-day decay. Position sizing on LAB should anchor to the underlying notional of $1.00 per share and to the trader's directional view on LAB stock.
LAB straddle setup
The LAB straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LAB near $1.00, the first option leg uses a $1.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LAB chain at a 36-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LAB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.00 | N/A |
| Buy 1 | Put | $1.00 | N/A |
LAB straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
LAB straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on LAB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on LAB
Straddles on LAB are pure-volatility plays that profit from large moves in either direction; traders typically buy LAB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
LAB thesis for this straddle
The market-implied 1-standard-deviation range for LAB extends from approximately $0.78 on the downside to $1.22 on the upside. A LAB long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current LAB IV rank near 21.43% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LAB at 117.10%. As a Healthcare name, LAB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LAB-specific events.
LAB straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LAB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LAB alongside the broader basket even when LAB-specific fundamentals are unchanged. Always rebuild the position from current LAB chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on LAB?
- A straddle on LAB is the straddle strategy applied to LAB (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With LAB stock trading near $1.00, the strikes shown on this page are snapped to the nearest listed LAB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LAB straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the LAB straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 117.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LAB straddle?
- The breakeven for the LAB straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LAB market-implied 1-standard-deviation expected move is approximately 22.00%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on LAB?
- Straddles on LAB are pure-volatility plays that profit from large moves in either direction; traders typically buy LAB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current LAB implied volatility affect this straddle?
- LAB ATM IV is at 117.10% with IV rank near 21.43%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.